Our Paris Technology & Life Sciences team advised AQEMIA on its $38 million financing round, bringing the total funds raised since inception to over $100 million in cumulative funding.
AQEMIA has developed a groundbreaking technological platform that combines quantum-inspired, atomic-scale physics with generative artificial intelligence enabling them to discover innovative drug candidates more rapidly.
This round was led by Cathay Innovation, followed by historical investors Wendel, Bpifrance Large Venture, Eurazeo, and Elaia.
The funding will support AQEMIA's development objectives, including the preparation for clinical trials and the further advancement of its platform for therapeutic molecule design.
The Goodwin team was led by Xavier Leroux and included Augustin Piqueras on corporate aspects. The firm has advised AQEMIA through multiple financing rounds since 2019.